ID: ALA4567975

Max Phase: Preclinical

Molecular Formula: C27H29ClO3

Molecular Weight: 436.98

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C[C@]12CC[C@@H]3c4cc(C(=O)/C=C/c5cccc(Cl)c5)c(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O

Standard InChI:  InChI=1S/C27H29ClO3/c1-27-12-11-19-20(23(27)8-10-26(27)31)7-6-17-14-25(30)22(15-21(17)19)24(29)9-5-16-3-2-4-18(28)13-16/h2-5,9,13-15,19-20,23,26,30-31H,6-8,10-12H2,1H3/b9-5+/t19-,20+,23-,26-,27-/m0/s1

Standard InChI Key:  QKRASJWWTHOWTH-JKDOLTLISA-N

Associated Targets(Human)

SK-N-SH 1499 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ECa-109 cell line 1254 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MGC-803 6426 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

SMMC-7721 5516 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

B16 5829 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 436.98Molecular Weight (Monoisotopic): 436.1805AlogP: 6.16#Rotatable Bonds: 3
Polar Surface Area: 57.53Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 7.50CX Basic pKa: CX LogP: 6.92CX LogD: 6.67
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.45Np Likeness Score: 1.25

References

1. Wang C, Li L, Fu D, Qin T, Ran Y, Xu F, Du X, Gao H, Sun S, Yang T, Zhang X, Huo J, Zhao W, Zhang Z, Shi X..  (2019)  Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.,  176  [PMID:31102934] [10.1016/j.ejmech.2019.04.071]

Source